Iovance Biotherapeutics, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?

Biotech Giants: SG&A Cost Trends from 2014 to 2023

__timestampIovance Biotherapeutics, Inc.Travere Therapeutics, Inc.
Wednesday, January 1, 2014933577259644696
Thursday, January 1, 20151239000079541000
Friday, January 1, 20162560200098015000
Sunday, January 1, 201721262000103958000
Monday, January 1, 201828430000103654000
Tuesday, January 1, 201940849000128951000
Wednesday, January 1, 202060210000135799000
Friday, January 1, 202183664000149883000
Saturday, January 1, 2022104097000220206000
Sunday, January 1, 2023106916000265542000
Loading chart...

Igniting the spark of knowledge

SG&A Cost Management: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Iovance Biotherapeutics, Inc. and Travere Therapeutics, Inc. have shown contrasting trends in their SG&A expenses from 2014 to 2023. Iovance's SG&A costs have increased by over 1,000% during this period, starting from approximately $9 million in 2014 to over $106 million in 2023. Meanwhile, Travere's expenses have surged by around 345%, from nearly $60 million to $266 million.

While both companies have seen significant increases, Travere's expenses have consistently been higher, peaking in 2023. This could indicate a more aggressive expansion strategy or higher operational costs. Understanding these trends can provide investors with insights into each company's financial strategies and operational efficiencies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025